ACP Issues Guidelines for Pharmacologic Treatment of Low Bone Density, Osteoporosis — Physician’s First Watch

Medical News |
September 16, 2008

ACP Issues Guidelines for Pharmacologic Treatment of Low Bone Density, Osteoporosis

The American College of Physicians has released recommendations for the pharmacologic treatment of patients with low bone density or osteoporosis.

The guidelines, published in the Annals of Internal Medicine, are based on efficacy data from more than 100 randomized, controlled trials or meta-analyses, as well as safety data from nearly 500 articles.

Among the recommendations:

  • Clinicians should offer pharmacotherapy (e.g., bisphosphonates, raloxifene) to women and men who have osteoporosis or have experienced fragility fractures.

  • Providers should consider treatment for adults at risk for osteoporosis, especially those who have T scores between –1.5 and –2.5, are older than age 62, or are receiving glucocorticoids.

  • Clinicians should assess the potential benefits and risks of each drug option in each patient before deciding on treatment. (The Annals article includes a helpful table summarizing the benefits and harms of various treatments.)

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.